Aligos Total Assets vs Common Stock Analysis

ALGS Stock  USD 25.51  2.52  10.96%   
Aligos Therapeutics financial indicator trend analysis is way more than just evaluating Aligos Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Aligos Therapeutics is a good investment. Please check the relationship between Aligos Therapeutics Total Assets and its Common Stock accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aligos Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
For more information on how to buy Aligos Stock please use our How to Invest in Aligos Therapeutics guide.

Total Assets vs Common Stock

Total Assets vs Common Stock Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Aligos Therapeutics Total Assets account and Common Stock. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Aligos Therapeutics' Total Assets and Common Stock is 0.47. Overlapping area represents the amount of variation of Total Assets that can explain the historical movement of Common Stock in the same time period over historical financial statements of Aligos Therapeutics, assuming nothing else is changed. The correlation between historical values of Aligos Therapeutics' Total Assets and Common Stock is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Assets of Aligos Therapeutics are associated (or correlated) with its Common Stock. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Common Stock has no effect on the direction of Total Assets i.e., Aligos Therapeutics' Total Assets and Common Stock go up and down completely randomly.

Correlation Coefficient

0.47
Relationship DirectionPositive 
Relationship StrengthWeak

Total Assets

Total assets refers to the total amount of Aligos Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Aligos Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Common Stock

Most indicators from Aligos Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Aligos Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aligos Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
For more information on how to buy Aligos Stock please use our How to Invest in Aligos Therapeutics guide.At this time, Aligos Therapeutics' Tax Provision is comparatively stable compared to the past year. Sales General And Administrative To Revenue is likely to gain to 3.82 in 2024, whereas Selling General Administrative is likely to drop slightly above 21.4 M in 2024.
 2022 2023 2024 (projected)
Depreciation And Amortization3.7M3.1M3.2M
Interest Income1.6M1.2M1.0M

Aligos Therapeutics fundamental ratios Correlations

-0.320.860.870.910.390.9-0.260.54-0.97-0.60.250.980.39-0.42-0.160.990.76-0.81-0.69-0.320.830.74-0.610.910.5
-0.32-0.46-0.45-0.430.22-0.460.940.290.470.81-0.22-0.430.510.110.89-0.36-0.380.670.531.0-0.31-0.630.55-0.43-0.53
0.86-0.460.980.93-0.050.94-0.550.47-0.91-0.840.270.910.3-0.27-0.240.840.89-0.9-0.88-0.460.970.95-0.810.930.83
0.87-0.450.980.90.040.9-0.520.59-0.9-0.840.470.90.31-0.39-0.180.850.95-0.86-0.84-0.450.970.92-0.760.90.84
0.91-0.430.930.90.111.0-0.440.48-0.93-0.70.210.930.13-0.49-0.180.920.85-0.79-0.92-0.430.870.89-0.881.00.61
0.390.22-0.050.040.110.10.40.44-0.30.240.140.320.21-0.530.180.43-0.050.020.210.22-0.09-0.130.270.11-0.43
0.9-0.460.940.91.00.1-0.490.44-0.93-0.730.180.930.1-0.47-0.230.910.83-0.81-0.93-0.460.870.91-0.891.00.63
-0.260.94-0.55-0.52-0.440.4-0.490.240.450.89-0.16-0.420.440.010.83-0.29-0.420.710.60.94-0.42-0.740.61-0.44-0.7
0.540.290.470.590.480.440.440.24-0.43-0.160.630.460.5-0.670.580.510.66-0.16-0.340.290.550.37-0.230.480.31
-0.970.47-0.91-0.9-0.93-0.3-0.930.45-0.430.73-0.2-1.0-0.280.370.33-0.98-0.760.90.750.47-0.85-0.840.68-0.93-0.59
-0.60.81-0.84-0.84-0.70.24-0.730.89-0.160.73-0.38-0.710.050.140.62-0.59-0.750.90.760.81-0.77-0.910.71-0.7-0.9
0.25-0.220.270.470.210.140.18-0.160.63-0.2-0.380.180.08-0.550.140.230.64-0.15-0.22-0.220.340.29-0.160.210.43
0.98-0.430.910.90.930.320.93-0.420.46-1.0-0.710.180.3-0.38-0.30.980.75-0.89-0.74-0.430.850.84-0.670.930.58
0.390.510.30.310.130.210.10.440.5-0.280.050.080.30.240.430.290.25-0.210.110.510.450.00.220.130.22
-0.420.11-0.27-0.39-0.49-0.53-0.470.01-0.670.370.14-0.55-0.380.24-0.24-0.49-0.490.050.440.11-0.21-0.360.42-0.49-0.01
-0.160.89-0.24-0.18-0.180.18-0.230.830.580.330.620.14-0.30.43-0.24-0.2-0.010.60.230.89-0.09-0.390.25-0.18-0.32
0.99-0.360.840.850.920.430.91-0.290.51-0.98-0.590.230.980.29-0.49-0.20.74-0.8-0.71-0.360.790.75-0.640.920.45
0.76-0.380.890.950.85-0.050.83-0.420.66-0.76-0.750.640.750.25-0.49-0.010.74-0.69-0.83-0.380.910.84-0.770.850.81
-0.810.67-0.9-0.86-0.790.02-0.810.71-0.160.90.9-0.15-0.89-0.210.050.6-0.8-0.690.70.67-0.83-0.870.64-0.79-0.78
-0.690.53-0.88-0.84-0.920.21-0.930.6-0.340.750.76-0.22-0.740.110.440.23-0.71-0.830.70.53-0.81-0.920.99-0.92-0.7
-0.321.0-0.46-0.45-0.430.22-0.460.940.290.470.81-0.22-0.430.510.110.89-0.36-0.380.670.53-0.31-0.630.55-0.43-0.53
0.83-0.310.970.970.87-0.090.87-0.420.55-0.85-0.770.340.850.45-0.21-0.090.790.91-0.83-0.81-0.310.87-0.730.870.85
0.74-0.630.950.920.89-0.130.91-0.740.37-0.84-0.910.290.840.0-0.36-0.390.750.84-0.87-0.92-0.630.87-0.870.890.84
-0.610.55-0.81-0.76-0.880.27-0.890.61-0.230.680.71-0.16-0.670.220.420.25-0.64-0.770.640.990.55-0.73-0.87-0.88-0.64
0.91-0.430.930.91.00.111.0-0.440.48-0.93-0.70.210.930.13-0.49-0.180.920.85-0.79-0.92-0.430.870.89-0.880.61
0.5-0.530.830.840.61-0.430.63-0.70.31-0.59-0.90.430.580.22-0.01-0.320.450.81-0.78-0.7-0.530.850.84-0.640.61
Click cells to compare fundamentals

Aligos Therapeutics Account Relationship Matchups

Aligos Therapeutics fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets146.5M265.3M235.4M146.7M151.5M193.1M
Short Long Term Debt Total14.3M13.0M14.5M12.6M11.1M10.6M
Other Current Liab753K14.1M22.5M12.9M13.6M11.7M
Total Current Liabilities13.8M30.3M39.0M33.1M23.9M27.1M
Total Stockholder Equity(64.9M)220.0M184.7M103.9M92.1M95.7M
Other Liab3.6M4.5M133K233K209.7K199.2K
Net Tangible Assets(64.9M)220.0M184.7M103.9M119.5M94.6M
Property Plant And Equipment Net16.1M14.9M15.0M12.5M9.8M11.1M
Current Deferred Revenue6.8M7.9M7.6M9.2M1.3M1.2M
Net Debt(55.2M)(207.4M)(172.4M)(68.8M)(124.6M)(130.8M)
Retained Earnings(66.2M)(174.7M)(303.1M)(399.1M)(486.8M)(462.5M)
Accounts Payable3.8M3.3M3.0M4.7M2.5M3.7M
Cash69.6M220.4M186.8M81.3M135.7M131.6M
Non Current Assets Total26.3M15.3M30.9M13.1M10.4M14.9M
Non Currrent Assets Other188K(3.3M)866K(2.5M)625K656.3K
Other Assets188K7.3K866K634K(2.4M)(2.3M)
Cash And Short Term Investments117.7M243.5M190.7M125.8M135.7M165.8M
Common Stock Shares Outstanding21.9M34.2M39.9M42.7M24.9M33.9M
Short Term Investments48.1M23.1M3.9M44.5M(70K)(66.5K)
Liabilities And Stockholders Equity146.5M265.3M235.4M146.7M151.5M193.1M
Non Current Liabilities Total197.6M15.0M11.7M9.7M35.5M51.1M
Capital Lease Obligations14.3M13.0M14.5M12.6M11.1M10.6M
Other Current Assets2.0M6.5M13.7M7.7M5.4M6.7M
Other Stockholder Equity(180.7M)395.0M487.3M502.6M578.3M308.4M
Total Liab211.4M45.3M50.6M42.8M59.4M70.8M
Net Invested Capital(64.9M)220.0M184.7M103.9M92.1M95.7M
Property Plant And Equipment Gross16.1M14.9M22.2M22.1M20.6M20.4M
Total Current Assets120.2M250.0M204.4M133.5M141.1M172.6M
Accumulated Other Comprehensive Income(115K)(188K)452K401K545K572.3K
Net Working Capital106.4M219.7M165.5M100.4M117.2M145.6M
Short Term Debt2.5M5.0M5.8M6.3M6.5M5.0M
Property Plant Equipment16.1M14.9M15.0M4.8M4.3M4.1M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Aligos Stock Analysis

When running Aligos Therapeutics' price analysis, check to measure Aligos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aligos Therapeutics is operating at the current time. Most of Aligos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aligos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aligos Therapeutics' price. Additionally, you may evaluate how the addition of Aligos Therapeutics to your portfolios can decrease your overall portfolio volatility.